mGlu₅ negative allosteric modulators: a patent review (2010 – 2012)

Bibliography

• Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
   PubMed Web of Science ®Google Scholar
• Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6
   PubMed Web of Science ®Google Scholar
• Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-46
   PubMed Web of Science ®Google Scholar
• Knopfel T, Kuhn R, Allgeier H. Metabotropic glutamate receptors: novel targets for drug development. J Med Chem 1995;38:1417-26
   PubMedGoogle Scholar
• Melancon BJ, Hopkins CR, Wood MR, Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 2012;55:1445-64
   PubMed Web of Science ®Google Scholar
• Conn PJ, Christopolous A, Lindsley CW. Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
   PubMed Web of Science ®Google Scholar
• Bridges TM, Lindsley CW. G-protein coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 2008;3:530-42
   PubMed Web of Science ®Google Scholar
• Niswender CM, Jones CK, Conn PJ. New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem 2005;5:847-57
   PubMedGoogle Scholar
• Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005;97:202-13
   PubMed Web of Science ®Google Scholar
• Kew JNC. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 2004;104:233-44
   PubMed Web of Science ®Google Scholar
• Emmitte KA. Recent advances in the design and development of novel negative allosteric modulators of mGlu5. ACS Chem Neurosci 2011;2:411-32
   PubMed Web of Science ®Google Scholar
• Rocher JP, Bonnet B, Bolea C, mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutics. Curr Top Med Chem 2011;11:680-95
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Emmitte KA. Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2009;12:446-57
   PubMedGoogle Scholar
• Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel 2008;11:655-65
   Google Scholar
• Jaeschke G, Wettstein JG, Nordquist RE, Spooren W. mGlu5 receptor antagonists and their therapeutic potential. Expert Opin Ther Pat 2008;18:123-42
   Web of Science ®Google Scholar
• Rodriguez AL, Williams R. Recent progress in the development of allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2007;10:715-22
   PubMedGoogle Scholar
• Gasparini F, Lingenhohl K, Stoehr N, Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. Neuropharmacology 1999;38:1493-503
   PubMed Web of Science ®Google Scholar
• Cosford ND, Tehrani L, Roppe J, 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003;46:204-6
   PubMed Web of Science ®Google Scholar
• Zhu CZ, Wilson SG, Mikusa JP, Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004;506:107-18
   PubMed Web of Science ®Google Scholar
• Pietraszek M, Sukhanov I, Maciejak P, Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005;514:25-34
   Google Scholar
• Busse CS, Brodkin J, Tattersall D, The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004;29:1971-9
   PubMed Web of Science ®Google Scholar
• Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 2004;47:342-50
   PubMed Web of Science ®Google Scholar
• Spooren WPJM, Vassout A, Neijt HC, Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000;295:1267-75
   PubMed Web of Science ®Google Scholar
• Nicolas LB, Kolb Y, Prinssen EPM. A combined marble burying-locomoter activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 2006;547:106-15
   PubMed Web of Science ®Google Scholar
• Jensen J, Lehmann A, Uvebrant A, Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005;519:154-7
   PubMed Web of Science ®Google Scholar
• Frisby CL, Mattsson JP, Jensen JM, Inhibition of transient lower esophageal sphincter relaxtation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005;129:995-1004
   PubMed Web of Science ®Google Scholar
• Morin N, Gregoire L, Gomez-Mancilla B, Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010;58:981-6
   PubMed Web of Science ®Google Scholar
• de Vrij FMS, Levenga J, van der Linde HC, Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31:127-32
   PubMed Web of Science ®Google Scholar
• Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49:1053-66
   PubMed Web of Science ®Google Scholar
• Lindemann L, Jaeschke G, Michalon A, CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 2011;339:474-86
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56
   PubMed Web of Science ®Google Scholar
• Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010;35:976-89
   PubMed Web of Science ®Google Scholar
• Silverman JL, Smith DG, Sukoff Rizzo SJ, Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 2012;4:131ra51
   PubMed Web of Science ®Google Scholar
• McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003;47:240-2
   PubMed Web of Science ®Google Scholar
• Chiamulera C, Epping-Jordan MP, Zocchi A, Reinforcing and locomoter stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2009;4:873-4
   Google Scholar
• Martin-Fardon R, Baptista MAS, Dayas CV, Weiss F. Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J Pharmacol Exp Ther 2009;329:1084-90
   PubMed Web of Science ®Google Scholar
• Kumaresan V, Yuan M, Yee J, Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav Brain Res 2009;202:238-44
   PubMed Web of Science ®Google Scholar
• Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 2006;31:778-86
   PubMed Web of Science ®Google Scholar
• Iso Y, Grajkowska E, Wroblewski JT, Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J Med Chem 2006;49:1080-100
   PubMed Web of Science ®Google Scholar
• Kenny PJ, Boutrel B, Gasparini F, Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) 2005;179:247-54
   PubMed Web of Science ®Google Scholar
• Tessari M, Pilla M, Andreoli M, Antagonism at metabotropic glutamate 5 receptor inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 2004;499:121-33
   PubMed Web of Science ®Google Scholar
• Platt DM, Rowlett JK, Spealman RD. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology (Berl) 2008;200:167-76
   PubMed Web of Science ®Google Scholar
• Lee B, Platt DM, Rowlett JK, Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther 2005;312:1232-40
   PubMed Web of Science ®Google Scholar
• Tronci V, Vronskaya S, Montgomery N, The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology (Berl) 2010;211:33-42
   PubMed Web of Science ®Google Scholar
• Kotlinska J, Bochenski M. Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. Eur J Pharmacol 2007;558:113-18
   PubMedGoogle Scholar
• Gass JT, Osborne MPH, Watson NL, mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology 2009;34:820-33
   PubMed Web of Science ®Google Scholar
• Adams CL, Short JL, Lawrence AJ. Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. Br J Pharmacol 2010;159:534-42
   PubMed Web of Science ®Google Scholar
• Besheer J, Grondin JJM, Salling MC, Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. J Neurosci 2009;29:9582-91
   PubMed Web of Science ®Google Scholar
• Gass JT, Olive MF. Role of protein kinase C epsilon (PKCepsilon) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell. Psychopharmacology (Berl) 2009;204:587-97
   PubMed Web of Science ®Google Scholar
• Schroeder JP, Spanos M, Stevenson JR, Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: blockade by the mGluR5 antagonist MPEP. Neuropharmacology 2008;55:546-54
   Google Scholar
• Lominac KD, Kapasova Z, Hannun RA, Behavioral and neurochemical interactions between group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Depend 2006;85:142-56
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Neal SJ, Smith DL, Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2012; doi:10.1016/j.neuropharm.2012.04.007
   Google Scholar
• Pecknold JC, McClure DJ, Appeltauer L, Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2:129-32
   PubMed Web of Science ®Google Scholar
• Structure of fenobam disclosed in Porter RHP, Jaeschke G, Spooren W, Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315:711-21
   Google Scholar
• Berry-Kravis EM, Hessl D, Coffey S, A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-71
   PubMed Web of Science ®Google Scholar
• Autism Therapeutics Press Release. Autism therapeutics announces purchase of Neuropharm Ltd. New York: 2011. Available from: http://www.autismtherapeutics.com/?p=238
   Google Scholar
• Raseglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2009;23:339-40
   Google Scholar
• Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease. Gut 2009;58:1192-9
   PubMed Web of Science ®Google Scholar
• Marin JCA, Goadsby PJ. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Exp Opin Investig Drugs 2010;19:555-61
   PubMed Web of Science ®Google Scholar
• Addex Pharmaceuticals Press Release. Development of ADX10059 ended for long-term use. Geneva: 2011. Available from: http://www.addextherapeutics.com/investors/press-releases/
   Google Scholar
• Dipraglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2009;23:328
   Google Scholar
• Addex Pharmaceuticals Press Release. Addex ADX48621 positive primate Parkinson's data. Geneva: 2009. Available from: http://www.addextherapeutics.com/investors/press-releases/
   Google Scholar
• Addex Pharmaceuticals Press Release. Addex reports positive top line phase IIa data for dipraglurant in Parkinson's disease levodopa-Induced dyskinesia (PD-LID). Geneva: 2012. Available from: http://www.addextherapeutics.com/investors/press-releases/
   Google Scholar
• Mavoglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2010;24:381
   Google Scholar
• Berg D, Godau J, Trenkwalder C, 056 treatment of levodopa-induced dyskinesias: results of 2 randomized clinical trials. Mov Disord 2011;26:1243-50
   PubMed Web of Science ®Google Scholar
• Gregoire L, Morin N, Ouattara B, The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsoniam Rel Disord 2011;17:270-6
   PubMed Web of Science ®Google Scholar
• Jacquemont S, Curie A, des Portes V, Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1
   PubMed Web of Science ®Google Scholar
• RG7090 structure. Available from: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=333211
   Google Scholar
• STX107 structure disclosed in reference 125
   Google Scholar
• Raboisson P, Breitholtz-Emanuelsson A, Dahllof H, Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg Med Chem Lett 2012;22:6974-9
   PubMedGoogle Scholar
• Rohof WO, Lei A, Hirsch DP, The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Ailment Pharmacol Ther 2012;35:1231-42
   PubMed Web of Science ®Google Scholar
• Stahle L, Karlsten R, Jonzon B, Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorders [Abstract PT444]. Abstracts of Papers: 14th World Congress on Pain. 28 August 2012; Milan, Italy
   Google Scholar
• Novartis AG. 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives. WO101058; 2012
   Google Scholar
• Novartis AG. 4-(Hetero)aryl-ethynyl-octahydro-indole-1-carboxylic acid esters. WO084873; 2012
   Google Scholar
• Daggett LP, Sacaan AI, Akong M, Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacol 1995;34:871-86
   PubMedGoogle Scholar
• Novartis AG. Combination Products. WO000763; 2010
   Google Scholar
• Novartis AG. Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's disease. WO127393; 2012
   Google Scholar
• Quik M, Cox H, Parameswaran N, Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-96
   PubMed Web of Science ®Google Scholar
• Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-47
   PubMed Web of Science ®Google Scholar
• Feuerbach D, Nozulak J, Lingenhoehl K, JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neurosci Lett 2007;416:61-5
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. A new crystalline form of 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. WO019100; 2010
   Google Scholar
• AstraZeneca AB. A crystalline form of 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. WO019101; 2010
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. 5-(Phenylisoxazolylethoxy)-triazol-3-yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders. WO040982; 2007
   Google Scholar
• AstraZeneca AB. Processes for the manufacture of 3-{4-methyl-5-[(1R)-1-(2-(3-methylphenyl)-2H-tetrazol-5-yl)-ethoxy]-4H-[1,2,4]triazol-3-yl}-pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-1,2,4-triazole, and (1R)-1[2-(3-methylphenyl)-2H-tetrazol-5-yl]ethanol. WO071559; 2010
   Google Scholar
• AstraZeneca AB. Tetrazole derivatives as modulators of metabotropic glutamate receptors (mGluRs). WO051556; 2009
   Google Scholar
• F. Hoffman-LaRoche AG. Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists. WO019989; 2012
   Google Scholar
• F. Hoffman-LaRoche AG. Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists. WO019990; 2012
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Enteric formulations of metabotropic glutamate receptor modulators. WO139876; 2012
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine. WO015269; 2008
   Google Scholar
• Merz Pharma Press Release. Positive results of the phase I study for treatment of late complications in Parkinson's disease. Frankfurt: 2011. Available from: http://www.autismtherapeutics.com/?p=238
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Pyrazolopyrimidines, a process for their preparation and their use as medicine. WO063487; 2010
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO052451; 2012
   Google Scholar
• Gasparini F, Andres H, Flor PJ, Kuhn R. [3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 2002;12:407-9
   PubMed Web of Science ®Google Scholar
• Santana L, Gonzalez-Diaz H, Quezada E, Quantitative structure—activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 2008;51:6740-51
   PubMed Web of Science ®Google Scholar
• Wyeth LLC. Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5). WO124047; 2010
   Google Scholar
• F. Hoffman-LaRoche AG. Imidazole derivatives as mGluR5 antagonists. WO006910; 2011
   Google Scholar
• Recordati Ireland, Ltd. Novel spiroheterocyclic compounds as mGlu5 antagonists. WO004400; 2012
   Google Scholar
• Guarneri L, Cova R, Angelico P, Effects of different drugs on the cystometrogram in conscious rats. Pharmacol Res 1991;24:175-87
   Google Scholar
• AstraZeneca AB. Sulphide bridged derivatives as modulators of mGluR5. WO123451; 2010
   Google Scholar
• Richter Gedeon Nyrt. Thieno[2,3-beta]pyridine compounds with mGluR activity. WO001185;2010
   Google Scholar
• Richter Gedeon Vegyeszeti Gyar Rt. New compounds. WO072095; 2007
   Google Scholar
• Vogel JR, Beer B, Cloudy DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology (Berl) 1971;21:1-7
   PubMed Web of Science ®Google Scholar
• Glaxo Group, Ltd. Tricyclic compounds as glutamate receptor modulators. WO049366; 2010
   Google Scholar
• Glaxo Group, Ltd. Novel compounds. WO151361; 2011
   Google Scholar
• H. Lundbeck A/S. Adamantyl diamide derivatives and uses of same. WO011570; 2010
   Google Scholar
• H. Lundbeck A/S. Adamantyl derivatives and uses of same. WO087758; 2011
   Google Scholar
• Cosford NDP, Roppe J, Tehrani L, [3H]-Methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003;13:351-4
   PubMed Web of Science ®Google Scholar
• O'Brien JA, Lemaire W, Chen T-B, A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 2003;64:731-40
   PubMed Web of Science ®Google Scholar
• Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-7
   PubMed Web of Science ®Google Scholar
• Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202
   PubMed Web of Science ®Google Scholar
• Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005;29:547-69
   PubMed Web of Science ®Google Scholar
• Lundbeck A/S. Bicyclo[3.2.1]octyl amide derivatives and uses of same. WO088365; 2012
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO085166; 2012
   Google Scholar
• Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO085167; 2012
   Google Scholar
• Recordati Ireland, Ltd. Heterocyclic derivatives as m-Glu5 antagonists. WO089119;2010
   Google Scholar
• Recordati Ireland, Ltd. Heterocyclic mGlu5 antagonists. WO029633; 2011
   Google Scholar
• F. Hoffman-LaRoche AG. Pyridine-2-yl-carboxylic acid amides. WO100050; 2010
   Google Scholar
• Sepracor, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5 and methods of use therof. WO 114971; 2010
   Google Scholar
• Burdi DF, Hunt R, Fan L, Design, synthesis, and structure—activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. J Med Chem 2010;53:7107-18
   PubMed Web of Science ®Google Scholar
• Vanderbilt Univ. Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035174; 2011
   Google Scholar
• Vanderbilt Univ. Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035186; 2011
   Google Scholar
• Vanderbilt Univ. Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035209; 2011
   Google Scholar
• Vanderbilt Univ. Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035214; 2011
   Google Scholar
• Vanderbilt Univ. 6-Alkyl-N-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO118563; 2012
   Google Scholar
• Deacon RMJ. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 2006;1:122-4
   PubMed Web of Science ®Google Scholar
• Thomas AM, Bui N, Perkins JR, Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 2012;219:47-58
   PubMed Web of Science ®Google Scholar
• Brocke KS, Staufner C, Luksch H, Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010;9:455-68
   PubMed Web of Science ®Google Scholar
• Teh J, Chen S. Metabotropic glutamate receptors and cancerous growth. WIREs Membr Transp Signal 2012;1:211-20
   PubMedGoogle Scholar
• Chen Y, Goudet C, Pin JP, Conn PJ. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 2008;73:909-18
   PubMedGoogle Scholar
• Rodriguez AL, Nong Y, Sekaran NK, A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 2005;68:1793-802
   Google Scholar